Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope Orange County, shared on LinkedIn:
“ESMO26 building upon options for our patients with Colorectal Cancer.
Our CLOVER Trial
- CCR5-targeting
- Leronlimab with
- Oral chemotherapy
- VEGF-inhibitor
- Enriched
- Regimen
ctDNA reductions compared to real world+dose response.
What’s cool is the power of ctDNA on multiple levels in CLOVER Trial.
- It acted as a surrogate to early response
- We were looking at 2 doses – we saw dose response
- We were able to collaborate Natera to find a real world comparator.
See how the CLOVER trial results compare to Sunlight regimen of Trifluridine/Tipiracil+/-BEV.
Realtime correlatives accelerating drug development.”
You can also read: 25 Posts Not to Miss from ESMO Congress 2026: Day 3
